The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats
Abstract
The objective is to assess the effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Male Wistar rats, 8-week-old, were categorized into four groups, which were the control (n = 9), diabetes (n = 9), infliximab-treated diabetes (n = 10), and FR167653-treated diabetes (n = 9) groups. Diabetes was induced by intraperitoneal injection of STZ (40 mg/kg). Thereafter, infliximab was injected intraperitoneally once a month (5.5 mg/kg) and FR167653 was administered orally by mixing with the rat chow (0.08%). The effects of infliximab and FR167653 on urinary albumin excretion were observed for 12 weeks. Body weight, blood sugar, 24-h urinary TNF-alpha, and 24-h urinary albumin/creatinine ratio (Ualb/Ucr) levels were determined at 1, 4, 8, and 12 weeks after the STZ-injection. Treatment of rats with STZ caused a significant loss of body weight, as well as polyuria and hyperglycemia within 1 week, while the urinary excretions of albumin and TNF-alpha were increased. Neither infliximab nor FR167653 affected body weight or blood sugar levels, whereas both decreased urinary albumin excretion, together with a modest decrease in the urinary excretion of TNF-alpha. These results suggest a role of TNF-alpha in the pathogenesis of diabetic nephropathy and show that TNF-alpha inhibition is a potential therapeutic strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, animal experiments have shown that TNF-α-blocking Infliximab improves renal function through attenuating fibrosis 20 and decreasing albumin excretion in a diabetic nephropathy rat model, 21,22”
From The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis (2025) · cites this paper as [22]
Citations
Cites
Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis
Hashimoto, S., Ochs, R., Komiya, S., & Lotz, M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9 · Cited by 500
Baert, F. J., D’Haens, G., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D. J., Geboes, K. J., & Rutgeerts, P. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70224-6 · Cited by 460
González-Gay, M. Á., Matias, J. M. D., González‐Juanatey, C., Garcı́a-Porrúa, C., Sanchez-Andrade, A., Martin, J. J., & Llorca, J. (2006) · PubMed · Cited by 313
mRNA Expression of Growth Factors in Glomeruli From Diabetic Rats
Nakamura, T., Fukui, M., Ebihara, I., Osada, S., Nagaoka, I., Tomino, Y., & Koide, H. (1993) · Diabetes · doi:10.2337/diab.42.3.450 · Cited by 307
Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy
Hasegawa, G., Nakano, K., Sawada, M., Uno, K., Shibayama, Y., Ienaga, K., & Kondo, M. (1991) · Kidney International · doi:10.1038/ki.1991.308 · Cited by 276
Moriwaki, Y., Yamamoto, T., Shibutani, Y., Aoki, E., Tsutsumi, Z., Takahashi, S., Okamura, H., Koga, M., Fukuchi, M., & Hada, T. (2003) · Metabolism · doi:10.1053/meta.2003.50096 · Cited by 270
Self-citationInhibition of endogenous TNF formation by pentoxifylline
Zabel, P., Schade, F. U., & Schlaak, M. S. (1993) · Immunobiology · doi:10.1016/s0171-2985(11)80356-6 · Cited by 183
Koshikawa, M., Mukoyama, M., Mori, K., Suganami, T., Sawai, K., Yoshioka, T., Nagae, T., Yokoi, H., Kawachi, H., Shimizu, F., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004121084 · Cited by 172
Kalantarinia, K., Awad, A. S., & Siragy, H. M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00237.x · Cited by 156
Sugimoto, H., Shikata, K., Wada, J., Horiuchi, S., & Makino, H. (1999) · Diabetologia · doi:10.1007/s001250051241 · Cited by 151
Cited by
Sorted by citations
Items 101–110 of 110
Updates in the management of diabetic nephropathy
Prakash, J. (2015) · Clinical Queries Nephrology · doi:10.1016/j.cqn.2015.11.001
Inhibition of inflammatory cytokines - potential new treatment for diabetic nephropathy
Correia, A. R. (2015) · OpenBU (Boston University)
The Role of the Immune System in the Pathogenesis of Diabetic
Velez, M.-G., & Bhalla, V. (2012)
Current literature in diabetes
(2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.887
Pasupulati, A. K., Nishad, R., Mukhi, D., Kethavath, S., Raviraj, S., Motrapu, M., & Kurukuti, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1212793/v1
Poteryaeva, O. N., & Федорович, У. И. (2021) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750821010066
Bioinformatics Analysis of Gene Networks Related to Diabetic Nephropathy and Endothelial Activation
Saik, O., & Klimontov, V. V. (2022) · International Multi-Conference on Engineering, Computer and Information Sciences (SIBIRCON) · doi:10.1109/sibircon56155.2022.10017112
Metadata
- Authors
- Moriwaki, Y., Inokuchi, T., Yamamoto, A., Ka, T., Tsutsumi, Z., Takahashi, S., & Yamamoto, T.
- Affiliations
- Hyogo Medical University (JP)
- Corresponding author
- Moriwaki, Yuji
- ORCID
- Yamamoto, Tetsuya
- Venue
- Acta Diabetologica
- Published
- 2007-09-01
- Volume
- 44
- Issue
- 4
- Pages
- 215-218
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2035793960
- Cited by
- 110
- References
- 19
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 9 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 4 · 2015: 7 · 2014: 9 · 2013: 5 · 2012: 15
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anti-TNF therapy, urinary albumin excretion, diabetic nephropathy, infliximab, FR167653, streptozotocin-induced diabetes, TNF-α, albuminuria
- MeSH terms
- Infliximab, Albuminuria, Animals, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Diabetes Mellitus, Experimental, Male, Pyrazoles, Pyridines, Tumor Necrosis Factor-alpha, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
